Biogen Advances Diranersen After Tau ASO Data

Company Biogen / Ionis Event Type Phase 2 clinical data presentation Modality Antisense oligonucleotide (ASO) Asset Diranersen (BIIB080) Target MAPT / tau mRNA Disease Area Alzheimer’s disease Summary Biogen presented Phase 2 CELIA data for diranersen, an intrathecally administered antisense oligonucleotide designed to reduce tau…